PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+11.58%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.46%
AUM
$3.59B
AUM Growth
+$3.59B
(-23%)
Cap. Flow
-$646M
Cap. Flow
% of AUM
-18%
Top 10 Holdings %
Top 10 Hldgs %
50.81%
Holding
126
New
21
Increased
12
Reduced
43
Closed
26
Top Buys
| 1 |
Janux Therapeutics
JANX
|
$43.8M |
| 2 |
Insulet
PODD
|
$23.5M |
| 3 |
Inhibikase Therapeutics
IKT
|
$19.3M |
| 4 |
Amylyx Pharmaceuticals
AMLX
|
$17.6M |
| 5 |
Penumbra
PEN
|
$17.4M |
Top Sells
| 1 |
Soleno Therapeutics
SLNO
|
$76.6M |
| 2 |
Biohaven
BHVN
|
$74.2M |
| 3 |
Tarsus Pharmaceuticals
TARS
|
$61.4M |
| 4 |
Apogee Therapeutics
APGE
|
$43.8M |
| 5 |
Amicus Therapeutics
FOLD
|
$35.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Janux Therapeutics
JANX
$1.38B
| $43.8M | 1.21% |
+817,895
| New | +$43.8M |
|
27
argenx
ARGX
$44.2B
| $41.5M | 1.14% |
67,471
-51,368
| -43% | -$31.6M |
|
28
Viking Therapeutics
VKTX
$3.02B
| $40.1M | 1.1% |
995,894
-704,093
| -41% | -$28.3M |
|
29
Akero Therapeutics
AKRO
$3.65B
| $33M | 0.91% |
1,185,592
-529,214
| -31% | -$14.7M |
|
30
Intuitive Surgical
ISRG
$158B
| $32.9M | 0.91% |
63,119
+5,000
| +9% | +$2.61M |
|
31
Acrivon Therapeutics
ACRV
$42.2M
| $32.3M | 0.89% |
5,360,858
| – | – |
|
32
Zymeworks
ZYME
$1.07B
| $31.2M | 0.86% |
2,130,020
-50,000
| -2% | -$732K |
|
33
Celcuity
CELC
$2.3B
| $30.9M | 0.85% |
2,362,279
| – | – |
|
34
Viridian Therapeutics
VRDN
$1.59B
| $28.5M | 0.79% |
1,486,508
-1,326,157
| -47% | -$25.4M |
|
35
Solid Biosciences
SLDB
$448M
| $27.6M | 0.76% |
6,906,646
| – | – |
|
|
36
Amylyx Pharmaceuticals
AMLX
$877M
| $25.6M | 0.71% |
6,774,348
+4,648,699
| +219% | +$17.6M |
|
37
Procept Biorobotics
PRCT
$2.11B
| $23.4M | 0.65% |
290,659
-25,000
| -8% | -$2.01M |
|
38
Nautilus Biotechnolgy
NAUT
$80.7M
| $21.2M | 0.58% |
12,594,211
| – | – |
|
|
CTNM
39
Contineum Therapeutics
CTNM
$297M
| $21.1M | 0.58% |
1,441,249
-75,419
| -5% | -$1.1M |
|
40
Natera
NTRA
$23B
| $19.8M | 0.55% |
125,000
-95,000
| -43% | -$15M |
|
|
41
Inhibikase Therapeutics
IKT
$129M
| $19.3M | 0.53% |
+5,925,000
| New | +$19.3M |
|
42
Orchestra BioMed
OBIO
$147M
| $18.4M | 0.51% |
4,592,556
| – | – |
|
|
43
Penumbra
PEN
$10.5B
| $17.4M | 0.48% |
+73,338
| New | +$17.4M |
|
|
SEPN
44
Septerna, Inc. Common Stock
SEPN
$628M
| $17.2M | 0.47% |
+750,000
| New | +$17.2M |
|
|
ORKA
45
Oruka Therapeutics, Inc. Common Stock
ORKA
$578M
| $16.4M | 0.45% |
845,567
-389,620
| -32% | -$7.55M |
|
46
Inhibrx
INBX
$403M
| $16.4M | 0.45% |
1,064,026
| – | – |
|
47
ADMA Biologics
ADMA
$4.03B
| $15.3M | 0.42% |
890,280
-169,920
| -16% | -$2.91M |
|
|
DRUG
48
Bright Minds Biosciences
DRUG
$307M
| $14.5M | 0.4% |
+403,649
| New | +$14.5M |
|
49
Arvinas
ARVN
$580M
| $14.2M | 0.39% |
740,749
-287,000
| -28% | -$5.5M |
|
50
Neurocrine Biosciences
NBIX
$13.5B
| $13.7M | 0.38% |
100,050
-112,178
| -53% | -$15.3M |
|